Gateway Investment Advisers LLC Has $277,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)


Share on StockTwits

Gateway Investment Advisers LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 771 shares of the medical device company’s stock after selling 164 shares during the period. Gateway Investment Advisers LLC’s holdings in DexCom were worth $277,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DXCM. Great West Life Assurance Co. Can boosted its position in DexCom by 2.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 62,449 shares of the medical device company’s stock worth $25,724,000 after buying an additional 1,377 shares during the period. IHT Wealth Management LLC lifted its position in shares of DexCom by 8.6% in the 3rd quarter. IHT Wealth Management LLC now owns 1,465 shares of the medical device company’s stock worth $604,000 after purchasing an additional 116 shares during the period. Chiron Capital Management LLC acquired a new position in shares of DexCom in the 3rd quarter worth approximately $41,000. Paces Ferry Wealth Advisors LLC acquired a new position in shares of DexCom during the 3rd quarter valued at $932,000. Finally, Advisor Partners LLC increased its stake in DexCom by 13.0% during the 3rd quarter. Advisor Partners LLC now owns 793 shares of the medical device company’s stock valued at $327,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 94.06% of the company’s stock.

In other news, EVP Paul R. Flynn sold 758 shares of the stock in a transaction dated Thursday, April 15th. The stock was sold at an average price of $400.00, for a total value of $303,200.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Steven Robert Pacelli sold 1,079 shares of the firm’s stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $368.82, for a total value of $397,956.78. Following the sale, the executive vice president now directly owns 21,524 shares in the company, valued at $7,938,481.68. The disclosure for this sale can be found here. Insiders have sold a total of 46,660 shares of company stock worth $17,323,976 in the last three months. Corporate insiders own 0.69% of the company’s stock.

Several analysts have recently issued reports on the stock. Citigroup reduced their target price on shares of DexCom from $485.00 to $480.00 and set a “buy” rating for the company in a research note on Friday, February 12th. Atlantic Securities initiated coverage on shares of DexCom in a research report on Thursday, April 15th. They set an “overweight” rating and a $438.00 price target for the company. Oppenheimer increased their price target on shares of DexCom from $415.00 to $449.00 and gave the company an “outperform” rating in a research report on Friday, February 12th. TheStreet upgraded shares of DexCom from a “c+” rating to a “b” rating in a research report on Thursday, February 11th. Finally, Raymond James increased their price target on shares of DexCom from $415.00 to $449.00 and gave the company an “outperform” rating in a research report on Friday, February 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the company. DexCom presently has an average rating of “Buy” and an average price target of $442.00.

NASDAQ DXCM opened at $388.91 on Wednesday. The stock has a market cap of $37.61 billion, a PE ratio of 160.71, a P/E/G ratio of 6.15 and a beta of 0.86. DexCom, Inc. has a 12 month low of $305.63 and a 12 month high of $456.23. The stock’s 50 day moving average is $367.18 and its 200 day moving average is $367.62. The company has a current ratio of 6.39, a quick ratio of 6.00 and a debt-to-equity ratio of 1.10.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 11th. The medical device company reported $0.91 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.91. The firm had revenue of $568.90 million for the quarter, compared to the consensus estimate of $558.41 million. DexCom had a return on equity of 27.29% and a net margin of 12.69%. On average, analysts forecast that DexCom, Inc. will post 3.07 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.

See Also: What Is an EV Stock?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.